MINDMED ANNOUNCES COLLABORATION WITH FORIAN

FOR IMMEDIATE RELEASE: August 24, 2021

CONTACT: mindmed@150bond.com

MINDMED ANNOUNCES COLLABORATION WITH FORIAN

TO ADVANCE DEVELOPMENT OF PERSONALIZED PSYCHIATRY FOR ANXIETY DISORDERS

New York, New York - Mind Medicine

(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired

therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical

and commercial decision-making.

MindMed and Forian will collaborate to develop

best practices for using real-world evidence ("RWE") information to help improve the health and lives of psychiatric patients.

Forian has deep domain experience in RWE and outcomes studies and has developed a variety of information products to serve the healthcare

Large, real-world health datasets drive discovery

and connections that can be missed in individual episodic health visits. Patterns emerge when multiple visits can be seen in a representative

"Our goal is to use real-world healthcare

data and deep digital phenotyping to achieve in-depth, precise and personalized characterizations of individuals with generalized anxiety

disorders and other conditions of interest for our drug development programs," said MindMed's Chief Medical Officer Dan Karlin,

MD MA. "By fully acknowledging each person's physiology, environment, and behavioral stressors, we ultimately aim for integrated

digital deep diagnoses to drive precision psychiatry for drug development and clinical treatment across our target therapeutic areas."

"Forian understands the power our real-world

evidence and unique data sets add to our healthcare and pharmaceutical partners," said Dan Barton, Chief Executive Officer of Forian.

"We are thrilled to collaborate with MindMed to help them deliver insights to improve the health of psychiatric patients."

The global pandemic and its overwhelming mental

health impacts underscore the need for tailored solutions and treatments that can be administered in a preventative rather than reactive

manner. MindMed is leveraging the recent advances in multi-omics, real-world data and artificial intelligence to help develop precise

and personalized psychiatry tools.

MindMed is a clinical-stage psychedelic medicine

biotech company that seeks to discover, develop, and deploy psychedelic-inspired medicines and therapies to address addiction and mental

illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including

psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience

to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol

MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.

Forian Inc. provides a unique suite of SaaS solutions,

data management capabilities and proprietary data and analytics to optimize and measure operational, clinical and financial performance

for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries,

manufacturers, cultivators and regulators. For more information, please visit the Company's website at www.forian.com.

Forward-Looking Statements

Certain statements in this news release related

to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective

in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future

events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results

expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words

such as "will", "may", "should", "could", "intend", "estimate",

"plan", "anticipate", "expect", "believe", "potential" or "continue",

or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements

regarding MindMed's successful collaboration with Forian, the ability to use RWE for MindMed's drug development programs,

access to RWE and the successful implementation of RWE data tools with patients. Although the Company believes that the expectations reflected

in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be

placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or

achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans

and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows;

limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws

and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory

scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines

industry; as well as those risk factors discussed or referred to herein and the risks described under the headings "Risk Factors"

in the Company's filings with the securities regulatory authorities in all provinces and territories of Canada which are available

under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove

incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has

attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others

that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information

are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice.

Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.